Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection (GS-US-320-1092)
IRB
CHLA-18-00070
A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection (GS-US-320-1092)
To find out the effects of tenofovir alafenamide (TAF) on children and adolescents with chronic hepatitis B.
Coordinator Contact
Sharon Tang
Contact Email
shatang@chla.usc.edu